Prokaryotics, Inc. Email Format
Pharmaceutical ManufacturingNew Jersey, United States2-10 Employees
Prokaryotics, Inc. is a small start-up biotechnology company formed by former Merck scientists, including the head of Merck’s Antimicrobial Early Discovery Unit, to optimize several early-stage antibiotic programs. It has worldwide rights to develop, manufacture and commercialize pre-clinical assets and programs targeting both Gram-negative and Gram-positive bacteria. The company is based in Union, New Jersey, and operates within the pharmaceutical manufacturing sector. Its work centers on advancing therapeutics aimed at multidrug-resistant bacteria and the global challenge of antibiotic resistance. In January 2026, Basilea Pharmaceutica entered into a research collaboration with Prokaryotics to develop a novel broad-spectrum antifungal for the treatment of severe invasive infections. The partnership indicates an expansion of Prokaryotics' collaboration portfolio into antifungal research.